Perkins Capital Management Inc. Purchases 1,525 Shares of Castle Biosciences, Inc. (NASDAQ:CSTL)

Perkins Capital Management Inc. lifted its position in Castle Biosciences, Inc. (NASDAQ:CSTL) by 4.7% during the 4th quarter, HoldingsChannel reports. The firm owned 34,165 shares of the company’s stock after buying an additional 1,525 shares during the period. Perkins Capital Management Inc.’s holdings in Castle Biosciences were worth $910,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Vanguard Group Inc. increased its stake in Castle Biosciences by 4.8% in the 4th quarter. Vanguard Group Inc. now owns 1,832,535 shares of the company’s stock worth $48,837,000 after acquiring an additional 83,783 shares during the last quarter. Principal Financial Group Inc. grew its holdings in shares of Castle Biosciences by 2.7% during the 3rd quarter. Principal Financial Group Inc. now owns 1,538,520 shares of the company’s stock valued at $43,879,000 after purchasing an additional 40,377 shares during the last quarter. Bellevue Group AG raised its position in Castle Biosciences by 3.7% in the 3rd quarter. Bellevue Group AG now owns 1,262,030 shares of the company’s stock worth $35,993,000 after purchasing an additional 44,929 shares during the period. Portolan Capital Management LLC lifted its stake in Castle Biosciences by 3.7% in the third quarter. Portolan Capital Management LLC now owns 1,255,628 shares of the company’s stock worth $35,811,000 after purchasing an additional 44,676 shares during the last quarter. Finally, State Street Corp boosted its position in Castle Biosciences by 9.8% during the third quarter. State Street Corp now owns 680,001 shares of the company’s stock valued at $19,394,000 after buying an additional 60,924 shares during the period. Hedge funds and other institutional investors own 92.60% of the company’s stock.

Castle Biosciences Trading Up 2.2 %

NASDAQ:CSTL opened at $20.52 on Monday. The company has a 50-day moving average price of $24.69 and a 200-day moving average price of $28.31. The stock has a market cap of $574.70 million, a price-to-earnings ratio of 102.61 and a beta of 0.98. The company has a current ratio of 7.78, a quick ratio of 7.64 and a debt-to-equity ratio of 0.02. Castle Biosciences, Inc. has a 12 month low of $16.97 and a 12 month high of $35.84.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on the company. Robert W. Baird boosted their target price on Castle Biosciences from $36.00 to $37.00 and gave the company an “outperform” rating in a research note on Friday, February 28th. Stephens reiterated an “overweight” rating and issued a $41.00 price objective on shares of Castle Biosciences in a research report on Thursday, January 2nd. Seven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $40.00.

Insider Buying and Selling at Castle Biosciences

In other Castle Biosciences news, Director Daniel Bradbury sold 7,867 shares of the company’s stock in a transaction dated Wednesday, February 5th. The shares were sold at an average price of $28.17, for a total value of $221,613.39. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider Derek J. Maetzold sold 22,639 shares of the firm’s stock in a transaction that occurred on Friday, March 7th. The shares were sold at an average price of $20.12, for a total transaction of $455,496.68. Following the transaction, the insider now directly owns 80,465 shares of the company’s stock, valued at $1,618,955.80. This represents a 21.96 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 44,204 shares of company stock valued at $1,055,988. 7.20% of the stock is currently owned by corporate insiders.

Castle Biosciences Profile

Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.